

May 27, 2023

То	То
Listing Department,	The Corporate Relations Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED	BSE LIMITED
Exchange Plaza,	Phiroz Jeejeebhoy Towers,
Bandra Kurla Complex, Bandra (E),	25 th floor, Dalal Street,
MUMBAI -400 051	MUMBAI -400 001
Company Code No. AUROPHARMA	Company Code No. 524804

Dear Sir,

Sub: Outcome of the Board Meeting held on May 27, 2023.

The Board of Directors of the Company at its meeting held today, May 27, 2023, has inter alia, considered and approved the standalone and consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Audited Financial Results of the Company along with the Audit Reports issued by the Statutory Auditors of the Company.

Pursuant to Regulation 33(3)(d) of SEBI Listing Regulations, we hereby confirm and declare that the Statutory Auditors of the Company, M/s. Deloitte Haskins & Sells, Chartered Accountants, have issued the audit reports on Standalone and Consolidated Financial Results of the Company for the fourth quarter and year ended March 31, 2023, with unmodified opinion.

The Board meeting commenced at 3.30 p.m. and concluded at 6.45 p.m.

Please take the information on record.

Yours faithfully, For AUROBINDO PHARMA LIMITED

B. Adi Reddy Company Secretary

Enclosures: as above.

(CIN: L24239TG1986PLC015190)

AUROBINDO PHARMA LIMITED

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel: +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: PlotNo.2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91402373 6370/23747340 Fax: +914023741080/23746833 Email: info@aurobindo.com Website: www.aurobindo.com

2

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

www.aurobindo.com

Regd. Office: Plot No.2, Maltrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

	(All amounts are in ₹ millions, unless otherwise state						
	STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR YEAR ENDED MARCH 31, 2023 AND						
-	UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2023						
	Quarter ended Year en						
	Particulars	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022	
		Unaudited	Unaudited	Unaudited	Audited	Audited	
		(refer note 8)		(refer note 7 & 8)		(refer note 7)	
1	Revenue from operations						
	(a) Net sales/ income from operations	34,838.0	34,184.7	28,778.3	126,075.4	112,500.7	
	(b) Other operating income	636.4	137.9	93.4	1,847.4	370.7	
	Total revenue from operations	35,474.4	34,322.6	28,871.7	127,922.8	112,871.4	
2	Other income						
	(a) Foreign exchange gain (net)	550.1	284.9	161.2	557.9	1,228.0	
	(b) Others	2,331.6	502.4	3,972.5	3,779.7	5,481.9	
	Total other income	2,881.7	787.3	4,133.7	4,337.6	6,709.9	
	Total income (1+2)	38,356.1	35,109.9	33,005.4	132,260.4	119,581.3	
2	Expenses						
	(a) Cost of materials consumed	20,574.6	19,886.7	14,207.8	72,476.9	57,839.3	
	(b) Purchase of stock-in-trade	152.2	134.3	11.5	892.3	168.1	
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-	(2,609.7)			(4,660.0)	455.1	
	progress	(2,005.7)	(1,250.0)	210.0	(4,000.07	455.1	
	(d) Employee benefits expense	4,067.7	4,183.0	3,863.8	16,418.8	16,000.4	
	(e) Finance costs	489.7	389.6	49.1	1,149.8	169.4	
	(f) Depreciation and amortisation expense	1,150.0	1,085.0	1,012.2	4,353.5	4,152.6	
	(g) Other expenses	6,371.3	6,625.0	5,500.9	25,485.6	23,674.5	
	Total expenses	30,195.8	31,065.0	24,863.3	116,116.9	102,459.4	
					,	,	
4	Profit before exceptional items and tax (1+2-3)	8,160.3	4,044.9	8,142.1	16,143.5	17,121.9	
	Exceptional items (refer note 5)		2	747.1		747.1	
	Profit before tax (4-5)	8,160.3	4,044.9	7,395.0	16,143.5	16,374.8	
	Tax expense (refer note 6)	.,	,	.,	,	20,01110	
	Current tax	1,738.4	1,141.5	254.1	4,070.2	3,797.0	
	Deferred tax	(26.1)	A		(230.8)	(1,969.3)	
	Total tax expense	1,712.3	1,056.7	(626.6)	3,839.4	1,827.7	
8	Profit for the period/year (6-7)	6,448.0	2,988.2	8,021.6	12,304.1	14,547.1	
	Other comprehensive income			-,/0	-,		
	Items that will not to be reclassified subsequently to profit or loss:						
	(a) Re-measurement of defined benefit liability	11.2	22.4	59.7	78.4	22.6	
	(b) Income-tax relating to items that will not be reclassified to profit or loss	(2.8)		(18.7)	(19.7)	(5.7)	
	, , , , , , , , , , , , , , , , , , ,	(=.0)	(5.0)	(10.7)	(12.17)	(5.7)	
10	Total comprehensive income for the period/year (8+9)	6,456.4	3,005.0	8,062.6	12,362.8	14,564.0	
11	Paid-up equity share capital (face value ₹ 1 per share)	585.9	585.9	585.9	585.9	585.9	
12	Other equity				178,555.8	170,587.5	
	Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualised)	
	(a) Basic (in ₹)	11.00	5.10	13.69	21.00	24.83	
	(b) Diluted (in ₹)	11.00	5.10	13.69	21.00	24.83	



v. _ y



Standalone balance sheet

St. No. As at 31.02.023 As at 3	Star	dalone balance sheet (All amounts are in i	₹ millions, unless o	otherwise stated)
Audited Audited Audited Audited ASSETS Asserts Audited Audited Non-current assets 94,268.7 34,87 Capital work in progress 2,309.9 2,258 Right-Guessets 93,268.7 34,87 Goodwill 94,268.7 34,87 Other intragible assets 1,139.2 212 Invactionation sets 91,200 66 Other intragible assets 1,219.2 75 Invactionation sets 2,201.7 65,84 Invactionationation sets 1,229.9 2,221.77 Invactionationationationationationationationa	SI.		1	And and a second se
Audited Audited Audited ASSETS Asserted Center nates Center nates Inconstruct assets 34,286.7 2,286.2 2,286.2 Split-diverk in progress 2,286.2 2,286.2 2,256.2 Split-diverk in progress 34,286.7 34,286.7 2,286.2 Split-diverk in progress 34,286.7 34,286.7 2,286.2 Split-diverk in progress 34,286.7 34,286.7 34,286.7 Split-diverk in progress 34,286.7 34,286.7 34,286.7 Split-diverk assets 1,332.2 32.2 35,207.7 55,87 Other financial assets 1,322.2 32.2 32.2 32.2 Income tax assets (net) 2,241.4 39.2 32.2 32.2 Income tax assets (net) 1,325.2 32.2 32.2 32.2 Income tax assets (net) 1,325.4 33.2 32.2 Intervision 1,325.5 42.2 32.2 32.2 Intervision 1,35.5.6 1,35.5.6 1,35.5.6	No.	Particulars		31.03.2022
ASST 35 ASST 35 ASST 35 AND Current assets 34,268,7 34,268,7 Property, Jant and equipment 2,290,9 2,25 Capital work in progress 34,208,7 34,208,7 Capital work in progress in progress 32,201,7 152,200,1 Investments 34,201,7 121,201,7 Investments 34,201,7 121,201,7 Investments 34,201,7 121,201,7 Investments 34,201,7 121,201,7 Investments 34,201,7 124,201,7 Investments 34,201,7 124,201,7 Investments 34,201,7 124,201,7			Audited	Audited
1Non-current assetsAugust and equipmentAugust and August	_			(refer note 7)
1Non-urner assetsAugust and equipmentAugust and august a		۵۶۶۴۲۵		
Property, plant and equipment 34,88.7 34,85.7 34,85.7 34,85.7 34,85.7 34,85.7 34,85.7 34,85.7 34,85.7 34,85.7 35,01 77.7 75.7	1			
Capalal work in progress 2,390.9 2,290.9 Right-Origo assets 97.0 0 Coddwill 97.0 0 Other intangible assets 1.39.2 2.8 Investments 260115 8.8,217.7 Coddwill 260115 8.8,217.7 Other intangible assets 260115 8.8,217.7 Investments 260115 8.8,217.7 Income tax assets 747.7 1.9 Other non-current assets 747.7 1.9 Income tax assets 1.02.2 9.5 Total non-current assets 1.02.2 9.5 Investments 41.25.2.6 33.5,6 Investments 41.25.2.6 33.5,6 Investments 1.02.2 9.3 Investments 1.2,26.5 44.24.2.8 Investments 1.2,26.5 1.5,85 Investments 1.2,26.5 1.5,85 Investments 1.2,26.5 1.5,85 Other innancial assets 1.9,97.4 1.2,25.5 Investinvents </td <td></td> <td></td> <td>34,268.7</td> <td>34,870.9</td>			34,268.7	34,870.9
Godwill917.0917.0Other intrapible savits1,139.2118Invastments22,011.55,28Laris22,011.55,28Trade receivables747.71,99Other innacial assets1,022.925Total non-current assets1,022.935Investoris1,022.93535Financial assets1,022.93535Investoris41,252.633,5546Rank balances other than cash and cash equivalents1,266.548Bank balances other than cash and cash equivalents1,265.515,86Laris1,265.515,85.515,85.5Total current assets1,265.515,85.515,85.5Total current assets1,265.515,85.515,85.5Total equity129,141.7171,27.3171,27.3I equity219,141.7171,27.3171,27.3Total equity219,141.7171,27.3171,27.3Total equity219,141.7171,27.3171,27.3Total equity219,141.7171,27.3171,27.3Total equity219,141.7171,27.3171,27.3Total equity219,141.7171,27.3<		Capital work-in-progress	2,390.9	2,251.5
Deter intengible assets1.1.9.21.1.9.2Financial assets82,217.765,80Trade receivables-82,217.7Other financial assets-82,217.7Other financial assets-82,217.7Other financial assetsOther financial assetsTrade receivablesOther financial assets1,222.6-Total non-current assets1,222.6-InventioriesFinancial assetsInventioriesFinancial assetsInventioriesInventioriesInventioriesInventioriesInventioriesInventioriesInventioriesInventioriesInventioriesInventioriesInventioriesInventioriesInventioriesInventiories <td< td=""><td></td><td>Right-of-use assets</td><td>550.1</td><td>731.8</td></td<>		Right-of-use assets	550.1	731.8
Financial assets 22,127, 65,90,00 Investments 26,011,5 Loans 26,011,5 Trade receivables 747,7 Other financial assets 1,002,9 Total non-current assets 1,002,9 Inventoris 1,102,9 Inventoris 1,102,9 Inventoris 1,202,9 Financial assets 1,202,9 Inventoris 1,205,6 Financial assets 1,205,6 Inventoris 1,205,6 Inventoris 1,205,6 Inventoris 1,205,6 Inventoris 1,205,6 Inventoris 1,205,6 Inventoris 1,205,6 Issets 1,205,6 Issets <td< td=""><td></td><td></td><td>194.1-2/02/04/07</td><td>69.9</td></td<>			194.1-2/02/04/07	69.9
Image: state in the state in			1,139.2	185.7
Loans26,01.58,28Trade receivables747.7198Income tax assets (net)28,21.422.8Unter financial assets1042.355Total non-current assets112,60.1117,60Inventories112,60.1117,60Inventories41,222.6335,60Financial assets41,252.6336,60Inventories45,602.6397,7Cash and cash equivalents12,265.544,255.5Bank balances other than cash and cash equivalents12,956.544,262.6Bank balances other than cash and cash equivalents7,394.255Other runent assets7,346.295,366.524,60.2Total current assets7,346.496,326.524,60.4Current assets7,346.496,326.521,555.615,855.0Other current assets7,346.496,326.521,555.8170,566.6I Equity Anar capital555.915,855.915,855.915,855.915,855.9Other equity178,555.8170,565.8170,367.1173,377.1I alguity178,151.122,93,86.521,550.8170,367.1Current liabilities42,91.160873.160I courter liabilities42,91.160873.115I courter liabilities21,555.8170,555.8170,555.8170,555.8I courter liabilities44,457.715,151.115,151.1I courter liabilities12,655.112,551.115,513.1I courter liabi				
Inder receivables 1 Other financial assets (net) 2,814.4 Other non-current assets 102.9 Total non-current assets 152,100.1 Importance 11,22,00.1 Importance 12,20,6 Importance 12,20,6 Importance 12,20,5 Importance 12,20,20 Importance 1				65,843.5
Other financial assets747.71.92Income tassets1,022.953Total non-current assets1,022.953Income tassets1,022.953Income tassets1,022.953Income tassets1,022.953Income tassets1,022.953Income tassets1,022.953Income tassets0.11Income tassets0.11Income tassets1,296.563,67Income tassets1,296.51,566.6Income tassets1,296.515,86Other financial assets1,595.615,86Other financial assets1,595.615,86Other current assets97,286.498,33Ite current assets97,286.498,33Ite current assets97,286.498,33Ite current assets17,285.8170,58Ite current assets170,585.9158,59Ite current assets170,585.8170,585.9Ite current assets170,585.9170,585.9Ite current assets170,585.9 <td< td=""><td></td><td></td><td>26,011.5</td><td>8,284.3</td></td<>			26,011.5	8,284.3
Income tax assets (net) 2,81.4. 2.95 Other non-current assets 1,042.9 33.55 Total non-current assets 14,252.6 33.55 Inventories 0.1 117,65 Inventories 0.1 117,65 Trade non-current assets 0.1 117,65 Inventories 0.1 12,856,602.6 Investments 0.1 12,855,602.6 Trade receivables 24,93 24,93 Cash and cash equivalents 1,295.5 42,83 Bank balances other than cash and cash equivalents 1,295.6 15,863 Other financial assets 7,384.2 8,563 Other current assets 7,384.2 8,563 Total ASSETS (1+2) 249,336.5 226,00 I Equity 249,336.5 226,00 I Equity 178,555.8 170,355.8 Other current assets 7,384.2 8,555.8 Total ASSETS (1+2) 249,336.5 226,00 I Equity 179,141.7 171,11 I Equity 179,141.7 172,11 I Equity 179,141.7 172,11 I abilities 3,340.3 3,02 I current liabilities 2,159,1 2,237 I current liabilitie				- 1,935.2
Uher non-current assets 1,042.9 55 Total non-current assets 152,100.1 117,63 2 Current assets 1,252.6 33,56 Inventories 1 1,295.5 33,56 Inventories 1,295.5 34,560.2.6 39,72 Cash and cash equivalents 24,9 24,9 24,9 Dank balances other than cash and cash equivalents 24,9 24,9 24,9 Loans 7,39,0 24,9 24,9 25,5 24,9 24,9 25,5 24,9 24,9 24,9 25,5 21,55,6 15,865 0,1 10,7,23,6,4 98,35 21,55,6 21,55,6 21,55,6 21,55,6 21,55,6 21,55,6 21,55,6 21,55,6 21,55,6 21,55,6 21,55,6 21,55,7 21,55,				2,954.3
Total non-current assets 152,100.1 117,65 Inventories 41,252.6 33,56 Inventories 0.1 1 Toda cash cash cash cash and cash equivalents 0.2 32,56.5 44,252.6 33,56 Investments 0.1 1 <t< td=""><td>- 1</td><td></td><td></td><td>531.3</td></t<>	- 1			531.3
2 Current assets Inventories Inventories Investments 41,252.6 33,56 Investments 41,252.6 33,56 Investments 45,602.6 33,72 Cash and cash equivalents 45,602.6 33,72 Bank balances other than cash and cash equivalents 79.9 3 Other current assets 79.9 3 Other financial assets 7,82.2 8,55 Total current assets 7,83.2 8,55 Total current assets 7,83.2 249,336.5 I Equity Amountain assets 7,83.2 8,55 Total current assets 7,84.2 85,59 Column Assets (1+2) 249,336.5 216,000 I Equity Amountain assets 178,555.8 170,555.8 I Equity Amountain assets 178,555.8 170,555.8 I Equity Amountain assets 179,555.8 170,555.8 I Equity Amountain assets 170,555.8 170,555.8 I Equity Amountain assets 179,555.8 170,555.8				117,658.4
Inventories41,252.633,56Financial assets0.1Trade receivables45,602.6Cash and cash equivalents1,295.5Bank balances other than cash and cash equivalents24,9Loans79.9Other financial assets7,842.2Other current assets7,842.2Total current assets7,842.2Cash and up to the current assets7,264.498,355216,000Total current assets7,264.498,355216,0001< Equity Abare capital			,,	
Financial assets 0.1 Investments 1,296.5 Trade receivables 1,296.5 Cash and cash equivalents 1,296.5 Bank balances other than cash and cash equivalents 1,296.5 Loans 7,9.9 Other financial assets 7,384.2 Other current assets 7,384.2 ToTAL ASSETS (1+2) 249,336.5 EQUITY AND LIABILITIES 249,336.5 Equity 585.9 Total equity 179,55.8 Total equity 179,55.8 Total equity 179,55.8 Isabilities 179,55.1 Non-current liabilities 179,55.1 Provisions 873.1 Deferred tax liability (net) 2,159.1 Total outstanding dues of micro enterprises and small enterprises 2,159.1 Itase liabilities 176.8 Provisions 21,55.1 Deferred tax liability (net) 176.8 Total outstanding dues of micro enterprises and small enterprises 21,55.1 Itaset ilabilities 176.8 Provisions 21,55.1 Deferred tax liability (net)	2	Current assets		
Investments0.1Trade receivables0.1Cash and cash equivalents1,296.5Bank balances other than cash and cash equivalents24.9Loans7,39Other financial assets1,595.6Other rurent assets7,384.2Requiry AND LABILITIES24.9,336.5Equity share capital24.9,336.5Other equity178,555.8Total current labilities179,11.7Iabilities179,11.7Non-current liabilities179,11.7Iabilities42.9.1Go Current liabilities42.9.1Iabilities21,259.1Iabilities3,461.3Solore equity3,461.3Current liabilities44,425.7Iabilities176.8Iabilities176.8Iabilities44,51.1Current liabilities44,25.7Iabilities176.8Solore equity176.8Current liabilities176.8Iabilities176.8Borrowings44,425.7Iabilities176.8Solore equital ideustrices176.8Solore equital ideustrices176.8Iabilities176.8Solore equital ideustrices176.8Current liabilities176.8Borrowings44,425.7Iabilities176.8Solore equital ideustrices176.8Solore equital ideustrices176.8Solore equital ideustrices176.8Solore equital ideustrices176.8Solore eq		Inventories	41,252.6	33,561.8
Trade receivables45,602.639,73Cash and cash equivalents1,266.544Bank balances other than cash and cash equivalents24.97.93Loans7,398Other funncial assets7,384.28,56Total current assets7,7384.28,56Total current assets97,236.498,35Current assets178,55.8170,55Current assets178,55.8170,55Current assets179,141.7171,17Cuase liabilities429,16Lease liabilities4429,16Lease liabilities3,461.33,002Provisions93,461.33,002Current liabilities176,81Current liabilities176,81Current liabilities12,558.11,65.1Current liabilities12,558.11,65.1Current liabilities12,558.11,65.1Current liabilities12,558.11,65.1Current liabilities <td></td> <td>Financial assets</td> <td></td> <td></td>		Financial assets		
Cash and cash equivalents1,296.5445Bank balances other than cash and cash equivalents24.924.9Loans79.955Other trinancial assets1,595.615.86Other current assets97,236.498,33TOTAL ASSETS (1+2)249,336.5216.00EQUITY AND LIABILITES249,336.5216.00I Equity share capital178,555.8170.55Other current labilities178,555.8170.55Financial liabilities429.160Financial liabilities2429.160Provisions27.152.43Sole current liabilities3,461.33,02Sole current liabilities176.8156.8Financial liabilities176.8156.8Current liabilities41,425.718,12Sole current liabilities166.122.55.8.1Financial liabilities176.8156.8Current liabilities176.8156.8Financial liabilities176.8156.8Current liabilities176.8156.8Sole current liabilities176.8156.8Sole current liabilities176.8156.8Current liabilities176.8156.8Sole current liabilities176.8156.8Current liabilities176.8156.8Current liabilities176.8156.8Current liabilities21.558.122.558.1Current liabilities21.558.123.558.1Current liabilities21.558.1 <td< td=""><td></td><td></td><td>C</td><td>0.1</td></td<>			C	0.1
Bank balances other than cash and cash equivalents24,924,9Loans7,9,98Other financial assets1,595,6Other current assets7,384,2Total current assets97,236,498,355216,000EQUITY AND LIABILITIES249,336,5Equity178,555,8Total equity178,555,8Total equity179,141,7Total equity179,141,7Total equity179,141,7Total iabilities429,1Iabilities21,591,1Provisions21,591,1Deferred tax liabilities3,461,3Financial liabilities176,8Financial liabilities176,8Iabilities176,8Total outsending dues of micro enterprises and small enterprises and small enterprisesOther current tabilities1,023,2Total outsending dues of micro enterprises and small enterprises21,581,1Other current tabilities1,023,2Total outsending dues of micro enterprises and small enterprises1,023,2Other current tabilities1,023,2Total outstanding dues of micro enterprises and small enterprises1,023,2Other moduli liabilities1,023,2Total outstanding dues of micro enterprises and small enterprises1,023,2Other financial liabilities1,023,2Other current tabilities1,023,2Other current tabilities21,558,1Other financial liabilities21,558,1Other financial liabilities21,558,1Other financial				39,732.4
Loans79.958Other financial assets1,595.615,88Other current assets7,738.48,55Total current assets97,236.498,35TOTAL ASSETS (1+2)249,336.5216,00EQUITY AND LIABILITIES585.955Equity share capital585.955Other equity178,555.8170,555Total equity179,141.7171,17Liabilities129,141.7171,17I Liabilities373.155Provisions873.155Deferred tax liabilities3,461.33,002Financial liabilities176,857.81176,857.8Deferred tax liabilities41,425.718,18Financial liabilities176.8127,558.1Deferred tax liabilities176.8126.8Financial liabilities176.8127.558.1Current liabilities176.8127.558.1Financial liabilities176.8127.558.1Provisions21,558.116,331Other financial liabilities136.3156.1Financial liabilities137.6127.558.1Financial liabilities137.6127.558.1Other current liabilities137.6127.558.1Total outstanding dues of micro enterprises and small enterprises21,558.1Other financial liabilities863.739.2Provisions226.61,05Current tax liability (net)224.3				482.1
Other financial assets1,595.615,86Other current assets7,384.28,56Total current assets97,236.498,35Current assets249,336.5216,00Equity NOD LIABILITIES249,336.5216,00Equity share capital585.9556Other equity178,555.8170,555Total equity179,141.7171,177I labilities429,160Provisions3,461.33,0023Current liabilities1,555.8Financial liabilities3,461.33,0024Current liabilities1,76.8Financial liabilities1,76.81,76.8Current liabilities1,76.81,76.8Current liabilities1,76.81,555.1Current liabilities1,76.81,555.1Financial liabilities1,76.81,555.1Current liabilities1,76.81,555.1Current liabilities1,76.81,555.1Current liabilities1,76.81,555.1Current liabilities1,022.24,86Current liabilities1,022.24,86Other financial liabilities2,555.116,33Current tax liability (net)2,24.32,24.3			P	25.7
Other current assets7,384.28,56Total current assets97,236.498,36TOTAL ASSETS (1-2)249,336.5216,00EQUITY AND LIABILITIES585.958Equity Share capital585.958Other equity178,555.8170,555Total equity179,141.7171,17Liabilities429.166Provisions873.15Deferred tax liabilities3,461.33,00Financial liabilities3,461.33,00Total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.122,158.1Other equity176.833Other equities445.124,232.4465.1Provisions44,425.718,1816,232.4486.3Other equities445.122,158.116,33Other equities445.122,158.116,33Other enterprises and small enterprises and small enterprises1,023.24,86Other current liabilities1,023.24,86465.1Current taibilities21,558.116,33366.7Other financial liabilities1,023.24,86465.1Other enterprises and small enterprises and small enterprises21,558.116,33Other current taibilities221,558.116,33366.7Other financial liabilities221,558.116,33366.7Other current taibilities366.130.224,86Other financial liabilities366.130.23 <td></td> <td></td> <td></td> <td>89.7</td>				89.7
Total current assets97,236.498,35TOTAL ASSETS (1+2)249,336.5216,00EQUITY AND LIABILITIES585.958Equity Equity share capital585.958Other equity178,555.8170,55Total equity179,141.7171,17Liabilities429.166Provisions873.15Deferred tax liabilities873.15Deferred tax liabilities3,461.33,02Ital outstanding dues of micro enterprises and small enterprises176.8125Total outstanding dues of creditors other than micro enterprises and small enterprises1,023.24,88Other financial liabilities1,023.24,884,83.7Current taibilities1,023.24,883,02Current liabilities1,023.24,883,02Current liabilities1,023.24,883,02Current liabilities1,023.24,884,83.7Deferrent cax liabilities21,558.11,023.24,88Current liabilities1,023.24,884,83.7Other financial liabilities1,023.24,884,83.7Deferrent tax liabilities21,558.11,023.24,88Other financial liabilities22,561,032,96Current taibilities22,561,032,961,03Current taibility (net)22,4324,961,03Current taibilities22,561,032,96Current taibility (net)22,4324,96 <td></td> <td></td> <td></td> <td>15,897.8</td>				15,897.8
TOTAL ASSETS (1+2) 249,336.5 216,00 EQUITY AND LIABILITIES 585.9 55 Equity 585.9 55 Other equity 178,555.8 170,58 Total equity 179,141.7 171,17 Labilities 179,141.7 171,17 Value 429.1 60 Financial labilities 429.1 60 Provisions 873.1 5 Deferred tax liabilities 3,461.3 3,00 Total equity 3,461.3 3,00 3 Current liabilities 41,425.7 18,18 Lease liabilities 41,425.7 18,18 Financial liabilities 176.8 12 Total outstanding dues of micro enterprises and small enterprises and small enterprises 21,558.1 16,33 Other financial liabilities 1023.2 4,883.7 92 Other financial liabilities 1023.2 4,883.7 92 Trade payables 1023.2 4,883.7 92 Other financial liabilities 192.3.7 193.2 24,88 Other financial liabilities 192.			**	98,351.1
1 EQUITY AND LIABILITIES 585.9 58 1 Equity 585.9 58 2 Other equity 178,555.8 170,55 1 Total equity 179,141.7 171,17 2 Liabilities 179,141.7 171,17 2 Non-current liabilities 429.1 60 Financial liabilities 429.1 60 Provisions 873.1 2 Deferred tax liability (net) 2,159.1 2,37 1 Total non-current liabilities 3,461.3 3,02 3 Current liabilities 176.8 15 1 Trade payables 176.8 15 1 total outstanding dues of micro enterprises and small enterprises 1,023.2 4,85 0 Trade payables 10,23.2 4,85 10,23.2 4,85 0 Trade payables 10,23.2 4,85 7,92 26.6 1,023.2 4,85 0 Current tax liabilities 10,23.2 4,85 10,23.2 4,85 10,23.2 4,85 0 Current tax		CALLER F.E. D. F. CANAR D. M.	57,230.4	36,551.1
1 Equity 585.9 585.9 2 Cher equity 178,555.8 170,585 4 Labilities 179,141.7 171,17 1 Labilities 179,141.7 171,17 2 Non-current liabilities 429.1 600 Financial liabilities 429.1 600 1 Provisions 873.1 95 0 Deferred tax liability (net) 2,159.1 2,377 7 total on-current liabilities 3,461.3 3,300 1 Current liabilities 176.8 195 1 Financial liabilities 176.8 195 1 Trade payables 176.8 195 1 total outstanding dues of micro enterprises and small enterprises 1,023.2 4,88 0 Other current liabilities 1,023.2 4,88 0 Current tax liability (net) 924.3 920.6		TOTAL ASSETS (1+2)	249,336.5	216,009.5
Equity share capital585.9550Other equity178,555.8170,555.8Total equity179,141.7171,177Liabilities179,141.7171,177Liabilities429.1600Provisions873.155Deferred tax liability (net)2,159.12,377Total non-current liabilities3,461.33,027Financial liabilities3,461.33,027Total non-current liabilities41,425.718,18Elease liabilities176.8176.8Financial liabilities176.8176.8Total non-current liabilities176.8156.3Current liabilities441,425.718,18Lease liabilities176.8156.3Trade payables465.1225Total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.1Other financial liabilities1,023.24,88Other current liabilities1,023.24,88Trade payables1,023.24,88Other financial liabilities1,023.24,88Other current liabilities296.61,023.2Provisions296.61,023.24,88Other current liabilities296.61,023.2Provisions296.61,023.24,88Other financial liabilities296.61,023.2Provisions296.61,023.24,88Other financial liabilities296.61,023.2Provisions296.61,023.24,88 <td></td> <td></td> <td></td> <td></td>				
Other equity178,555.8170,552Total equity179,141.7171,17Liabilities179,141.7171,17Liabilities41,17171,17Lease liabilities429.160Provisions873.15Deferred tax liability (net)2,159.12,37Total non-current liabilities3,461.33,02Borrowings41,425.7118,18Lease liabilities176.815Financial liabilities176.815Current liabilities176.815Trade payables176.815total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.1Other financial liabilities1,023.24,88Other financial liabilities863.792Other financial liabilities863.792Other financial liabilities22,558.11,023.2Other financial liabilities22,558.11,023.2Other financial liabilities924.3100	1			
Total equity179,141.7171,17Liabilities179,141.7171,17Non-current liabilities429.160Financial liabilities429.160Provisions873.19Deferred tax liability (net)2,159.12,37Total non-current liabilities3,461.33,023Current liabilities176.81Financial liabilities176.811Borrowings41,425.718,181Lease liabilities176.811Total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.116,33Other financial liabilities1,023.24,884,86Other financial liabilities1,023.24,883,92Other financial liabilities22,558.116,331,92Total outstanding dues of creditors other than micro enterprises and small enterprises21,558.116,33Other financial liabilities363.792226.61,02Total outstanding dues of creditors other than micro enterprises and small enterprises224,561,02Other rurent liabilities226.61,02226.61,02Current tax liability (net)924.3111				585.9
IabilitiesIabilitiesNon-current liabilities429.1Financial liabilities429.1Lease liabilities429.1Provisions873.1Deferred tax liability (net)2,159.1Total non-current liabilities3,461.3SCurrent liabilitiesFinancial liabilities3,461.3Borrowings41,425.7Lease liabilities176.8Trade payables45.1total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.1Other financial liabilities1,023.2Other rurrent liabilities1,023.2Other rurrent liabilities22,558.1Other rurrent liabilities1,023.2Other rurrent liabilities22,558.1Other rurrent liabilities1,023.2Other rurrent liabilities22,558.1Other rurrent liabilities3,263.7Other rurrent liabilities22,558.1Other rurrent liabilities23,24.3				170,587.5
2Non-current liabilities429.1600Financial liabilities429.1600Provisions873.15Deferred tax liability (net)2,159.12,37Total non-current liabilities3,461.33,0273Current liabilities3,461.33,027Financial liabilities176.815Borrowings41,425.718,18Lease liabilities176.815Trade payables465.122total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.1Other financial liabilities1,023.24,855Other financial liabilities863.732Provisions236.61,033Other financial liabilities863.732Other financial liabilities36.136.1Other financial liabilities1,023.24,855Other financial liabilities36.330.2Financial liabilities3,0330.2Other financial liabilities1,023.24,855Other financial liabilities36.330.2Other financial liabilities36.330.2Other urrent liabilities36.330.2Financial liabilities36.330.2Other urrent liabilities36.330.2Other urrent liabilities30.330.2Other urrent liabilities30.330.3Other urrent liabilities30.330.3Other urrent liabilities30.330.3Ot		Total equity	179,141.7	171,173.4
2Non-current liabilities429.1600Financial liabilities429.1600Provisions873.150Deferred tax liability (net)2,159.12,37Total non-current liabilities3,461.33,0223Current liabilities3,461.33,022Financial liabilities176.8150Financial liabilities176.8150Trade payables465.122total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.1Other financial liabilities1,023.24,855Provisions20,661,003.2Other financial liabilities863.7320 ther financial liabilities863.7320 ther financial liabilities23,558.11,003.20 ther financial liabilities23,558.11,003.20 ther financial liabilities36.33,023.20 ther financial liabilities3,651.33,023.20 ther financial liabilities1,023.24,8550 ther financial liabilities36.33,023.20 ther current liabilities36.33,		Liabilities		
Lease liabilities429.1600Provisions873.192Deferred tax liability (net)2,159.12,37Total non-current liabilities3,461.33,02SCurrent liabilities41,425.718,18Financial liabilities41,425.718,18Borrowings41,425.718,18Lease liabilities176.819Trade payables465.129total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.1Other financial liabilities1,023.24,88Other current liabilities21,503.24,88Other financial liabilities21,558.116,33Other current liabilities21,503.24,88Other financial liabilities21,523.24,88Other current liabilities21,523.24,88Other current liabilities296.61,03Provisions296.61,03296.6Current tax liability (net)924.3924.3	2			
Provisions873.1Deferred tax liability (net)2,159.1Total non-current liabilities3,461.33,461.33,023Current liabilitiesFinancial liabilities41,425.7Borrowings41,425.7Lease liabilities176.8Trade payables1total outstanding dues of micro enterprises and small enterprises and465.1221,558.116,31Other financial liabilities1,023.2Ages863.7Provisions296.6Current tax liability (net)924.3		Financial liabilities		
Deferred tax liability (net)2,159.12,37Total non-current liabilities3,461.33,023Current liabilities3,461.33,024Financial liabilities41,425.718,18Borrowings41,425.718,18176.8Lease liabilities176.815Trade payables465.129total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.116,31Other financial liabilities1,023.24,86Other current liabilities863.792Provisions296.61,03Current tax liability (net)924.310		Lease liabilities	429.1	605.8
Total non-current liabilities3,461.33,023Current liabilities		a Province Control of	873.1	50.3
3Current liabilities Financial liabilities Borrowings Lease liabilities Trade payables total outstanding dues of micro enterprises and small enterprises and small enterprises ottal outstanding dues of creditors other than micro enterprises and small enterprises ottal outstanding dues of creditors other than micro enterprises and small enterprises other current liabilities Provisions Current tax liability (net)0, 10, 20, 20, 20, 20, 20, 20, 20, 20, 20, 2				2,370.3
Financial liabilities41,425.718,18Borrowings41,425.718,18Lease liabilities176.815Trade payables176.815total outstanding dues of micro enterprises and small enterprises and small enterprises465.129total outstanding dues of creditors other than micro enterprises and small enterprises21,558.116,31Other financial liabilities1,023.24,89Other current liabilities863.792Provisions296.61,03Current tax liability (net)924.310		Total non-current liabilities	3,461.3	3,026.4
Financial liabilities41,425.718,18Borrowings41,425.718,18Lease liabilities176.815Trade payables176.815total outstanding dues of micro enterprises and small enterprises and small enterprises465.129total outstanding dues of creditors other than micro enterprises and small enterprises21,558.116,31Other financial liabilities1,023.24,89Other current liabilities863.792Provisions296.61,03Current tax liability (net)924.310	3	Current liabilities		
Borrowings41,425.718,18Lease liabilities176.815Trade payables176.815total outstanding dues of micro enterprises and small enterprises and small enterprises465.129total outstanding dues of creditors other than micro enterprises and small enterprises21,558.116,31Other financial liabilities1,023.24,89Other current liabilities863.792Provisions296.61,03Current tax liability (net)924.310	ſ			
Lease liabilities176.8155.1Trade payables465.129total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.116,31Other financial liabilities1,023.24,89Other current liabilities863.792Provisions296.61,03Current tax liability (net)924.392			41,425.7	18,186.2
Trade payables465.1total outstanding dues of micro enterprises and small enterprises and small enterprises21,558.1total outstanding dues of creditors other than micro enterprises and small enterprises21,558.1Other financial liabilities1,023.2Other current liabilities863.7Provisions296.6Current tax liability (net)924.3				156.9
total outstanding dues of creditors other than micro enterprises and small enterprises21,558.116,31Other financial liabilities1,023.24,89Other current liabilities863.792Provisions296.61,03Current tax liability (net)924.392		Trade payables		
Other financial liabilities1,023.24,89Other current liabilities863.792Provisions296.61,03Current tax liability (net)924.392			465.1	298.9
Other current liabilities863.792Provisions296.61,03Current tax liability (net)924.3			······································	16,312.6
Provisions 296.6 1,03 Current tax liability (net) 924.3		STARTE DESCRIPTION DESCRIPTION		4,894.3
Current tax liability (net) 924.3		Terror Distribution and Contemporation and Contempo		927.2
				1,033.6
DD,/33.5 41,80				41 900 7
			00,755.5	41,003./
TOTAL EQUITY AND LIABILITIES (1+2+3) 249,336.5 216,00		TOTAL EQUITY AND LIABILITIES (1+2+3)	249,336.5	216,009.5



к.<u>-</u>Ч MABAD.

Standalone statement of cash flows

SI.			otherwise stated
1 a 1		For the year	For the year
10.	Particulars	ended	ended
	Fariculars	31.03.2023	31.03.2022
		Audited	Audited (refer note 7)
10	CASH FLOW FROM OPERATING ACTIVITIES		note 7
_ r	Net profit before tax	16,143.5	16,374.8
1	Adjustments for :		
	Depreciation, amortisation and impairment expense	4,353.5	4,152.0
	Exceptional items (refer note 5)	-	747.:
	Allowance for credit losses on trade receivables and other advances (net)	186.3	(178.0
	Provisions no longer required written back Unrealised foreign exchange gain on non derivative assets (net)	(51.6)	(89.6
	Mark-to-market loss/(gain) on derivative foreign currency forward contracts	(139.9) (87.8)	(125. (274.)
	(Profit)/loss on sale of property, plant and equipment (net)	(133.5)	311.
	Dividend income	(1,648.7)	(4,509.
	Finance costs	1,130.7	152.
	Interest income	(1,857.1)	(491.
	Operating profit before working capital changes Movements in working capital:	17,895.4	16,068.
	Increase)/decrease in trade receivables	15 266 0	15 022
	Increase)/decrease in inventories	(5,366.0)	15,923.0
	Decrease in loans	(7,399.0) 10.5	11,328. 29.
	Decrease/(increase) in other financial assets	14,537.6	(54.
	Decrease in other current/non-current assets	727.0	1,818.
	ncrease/(decrease) in trade payables	788.9	(1,044.
1	ncrease in provision for employee benefits	82.9	74.
	ncrease other financial liabilities	3.8	
	Decrease)/increase in other current liabilities	(63.6)	43.
	Cash generated from operating activities	21,217.5	44,187.8
- 11	ncome-tax paid (net) Net cash flow generated from operating activities (A)	(3,005.9) 18,211.6	(6,920. 37,267.
ľ	the cash now generated norm operating activities (A)	10,211.0	57,207
2	CASH FLOW FROM INVESTING ACTIVITIES		
1	Purchase of property, plant and equipment including movement in capital work-in-progress,	(3,537.5)	(6,140.6
-	capital advances and capital creditors		
- 1	Purchase of intangible assets and intangible assets under development	(45.4)	(32.4
	Proceeds from sale of property, plant and equipment and intangibles	232.2	6,434.3
	Purchase of non-current investments	(9,391.0)	(18,857.9
	Acquisition of business including certain assets (refer note 4(a))	(1,689.2)	7.65
	Proceeds from current investments		1,290.4
	Dividend received from subsidiaries	1,648.7	4,521.9
	Loans made to subsidiaries/ joint venture Loans repaid by subsidiaries/ joint venture	(26,350.0)	(7,500.0
	nterest received	3,737.5 797.1	3,634.1 515.0
	Bank balances not considered as cash and cash equivalents (net)	0.8	515.
	Net cash flow used in investing activities (B)	(34,596.8)	(16,135.:
	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds/(repayment) of current borrowings (net)	22,873.1	(21,541.3
- 10	Repayment of lease liabilities, net nterest paid	(209.6)	(209.5 (87.6
	Dividend paid on equity shares	(1,073.4) (4,395.3)	(2,637.0
		(1,00010)	(2)0071
- 1	Net cash generated from/(used) in financing activities (C)	17,194.8	(24,475.4
	Not increase (Idearcose) in each and each acuivalents (A, D, C)		10.040
	Net increase/(decrease) in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning of the year	809.6	(3,343.4
	Effect of exchange differences on cash and cash equivalents	482.1 4.8	3,835. (10.
ľ		4.0	(10.
6	Cash and cash equivalents at the end of the year	1,296.5	482.1
1	Cash and cash equivalents comprises of:		
- 1	Cash on hand	0.3	1.
1	Balance with banks:		
	Current accounts Cash credit accounts (net)	1,058.3	144.
- 1	Cash and cash equivalents considered for cash flows	237.9	336.
– L	Chartered for cash nows	1,296.5	482.
ľ			
	O ACCOUNTANTS IT		
ľ			

NOTES:

- 1 The above standalone financial results of Aurobindo Pharma Limited ("the Company") have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 27, 2023. The results for the year ended March 31, 2023 has been audited and for the guarter ended March 31, 2023 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2023 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2023.
- 3 The Company operates in only one reportable segment viz., 'Pharmaceutical Products'.
- 4 a) The Board of Directors of the Company at its meeting held on March 28, 2022 had approved the acquisition of business including certain assets of Veritaz Healthcare Limited (Veritaz). Consequently the Company entered into a definitive agreement with Veritaz for the said acquisition for a total consideration of ₹ 1,689.2 and obtained control w.e.f. April 1, 2022 over such business and assets.

b) The Board of Directors of the Company at its meeting held on June 17, 2022 had approved investment in GLS Pharma Limited (GLS) through subscription of 204,819 equity shares for an aggregate consideration of ₹ 93.5 (constituting 17% of the equity share capital of GLS) and acquisition of 409,339 equity shares from the selling shareholders for an aggregate consideration of ₹ 187 (constituting of 34% of equity share capital of GLS). During the quarter ended June 30, 2022, the Holding Company subscribed to 204,819 equity shares of GLS consequent to execution of share subscription and purchase agreement. During the year on satisfaction of the closing conditions, the Company acquired the additional 409,339 equity shares. As at March 31, 2023 the Company holds 51% of the equity shares in GLS.

c) During the previous year, pursuant to Board approvals obtained, the following units were transferred within the Group:

(i) The undertaking of Unit 10 located at Multiproduct Special Economic Zone, Naidupet, Mandal, SPSR Nellore District, Andhra Pradesh, transferred to its whollyowned subsidiary APL Healthcare Limited through a slump sale w.e.f April 1, 2021.

(ii) The undertaking of Unit-4 of the Company located at Pashamylaram, Patancheru Mandal, Sangareddy district, Telangana, transferred to Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company w.e.f. July 1, 2021.

(iii) The undertaking of Unit-16 of the Company located at TSIIC, SEZ, Polepally Village, Jadcherla Mandal, Mahbubnagar district, Telangana, transferred to Wytells Pharma Private Limited, a wholly owned step-down subsidiary of the Company and 100% subsidiary of Eugia Pharma Specialities Limited w.e.f June 1, 2021.

(iv) The undertaking of Unit 18 of the Company located at Survey No.69, 70, 71 & 72, Indrakaran Village, Kandi Mandal, Sangareddy District - 502203, Telangana, to Auro Vaccines Private Limited, a wholly owned subsidiary of the Company w.e.f. January 1, 2022.

Consequent to the above transfers/acquisitions, the results of the current quarter/year are strictly not comparable to the previous quarters/year.

d) The Board of Directors of the Company at its meeting held on February 9, 2023 and subsequently on March 23, 2023, Shareholders of the Company approved through postal ballot the transfer of certain Active Pharmaceutical Ingredients (API) busines units (Unit I, VIII, IX, XI, XIV and RC – 02) for consideration of ₹33,031.7 to its wholly owned subsidiary, Apitoria Pharma Private Limited (APPL) (formerly known as Auro Pharma India Private Limited) on going concern basis by way of a slump sale w.e.f April 01, 2023.

Subsequent to year end, on April 01, 2023 Board of Directors of the Company approved the transfer of two API units (Unit V and XVII) for consideration of ₹5,026.2 to its wholly owned subsidiary, APPL on going concern basis by way of a slump sale w.e.f April 01, 2023.

- 5 Exceptional item of ₹747.1 for the quarter and year ended March 31, 2022 represents impairment of investment relating to a subsidiary.
- 6 During the quarter ended March 31, 2022, the Company elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for income tax for the year ended March 31, 2022 and remeasured its deferred tax assets /liabilities based on the rate prescribed in the said Section. The impact of this change has been recognised in the statement of profit and loss during the year ended March 31, 2022.
- 7 The standalone financial results of the Company for the quarter and year ended March 31, 2022, were audited by the M/s BSR & Associates LLP, Chartered Accountants, the predecessor auditor, who have expressed an unmodified opinion.
- 8 The figures for the current quarter and quarter ended March 31, 2022, are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and March 31, 2022, respectively and published year to date figures up to third quarter ended December 31, 2022 and December 31, 2021, respectively, which were subject to limited review by the statutory auditors.

ASKIN CHARTERED 0 ACCOUNTANTS

Place: Hyderabad Date : May 27, 2023



By Order of the Board



K.Nithyananda Reddy Vice Chairman & Managing Director DIN-01284195

Chartered Accountants KRB Towers Plot No.1 to 4 & 4A 1st, 2nd & 3rd Floor Jubilee Enclave, Madhapur Hyderabad-500 081 Telangana, India

Tel: +91 40 7125 3600 Fax: +91 40 7125 3601

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2023 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2023 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of audited standalone financial results for year ended March 31, 2023 and unaudited standalone financial results for the quarter ended March 31, 2023" of **AUROBINDO PHARMA LIMITED** ("the Company"), ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Audited Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2023:

- 1. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2023

With respect to the Standalone Financial Results for the quarter ended March 31, 2023, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2023, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2023

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2023 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2023 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2023 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2023

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2023 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.

y

- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Company to express an opinion on the Annual Standalone Financial Results.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2023

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2023 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

M

Other Matters

The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

Our report on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS** Chartered Accountants (Firm's Registration No. 008072S)

C Manish Muralidhar (Partner) (Membership No. 213649)

Place: Hyderabad Date: May 27, 2023 UIDN: 23213649BGVBYQ9002

2

AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190) www.aurobindo.com

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(All amounts are in ₹ millions, unless otherwise stated)

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR YEAR ENDED MARCH 31, 2023 AND

Quarter ended Year ended Year ended					ended
Particulars	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
	Unaudited	Unaudited	Unaudited	Audited	Audited
	(refer note 9)	onduited	(refer note 9 &		(refer note 10
	(refer note 5)		(refer fibite 5 tc 10)		(relef note to
1 Revenue from operations	60 006 0	60.070.7	57.052.4		222.005
(a) Net sales/ income from operations	63,786.7	63,879.7	57,953.4	246,171.3	233,665.
(b) Other operating income	942.9	191.6	140.3	2,382.5	889.
Total revenue from operations	64,729.6	64,071.3	58,093.7	248,553.8	234,554.
2 Other income	226.5	121.2	197.2		699.
(a) Foreign exchange gain (net)	226.5 1,122.6	121.3 805.2	291.6	2,905.9	2,503
(b) Others Total other income	1,122.0	926.5	488.8	2,905.9	3,203
Total income (1+2)	66,078.7	64,997.8	58,582.5	2,503.5	237,758
3 Expenses (a) Cost of materials consumed	26,705.7	26,214.9	19,044.2	96,525.1	72 710
(b) Purchase of stock-in-trade			1. C.	1.5.1	73,718
	5,887.5	5,379.5	4,830.8	20,504.3	19,517
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(3,283.5)	(2,518.8)	1,367.0	(4,096.8)	8,166
(d) Employee benefits expense	8,519.0	9,217.2	8,532.3	35,222.5	34,509
(e) Finance costs	556.0	449.6	92.1	1,404.8	486
(f) Foreign exchange loss (net)	5			395.8	-
(g) Depreciation and amortisation expense	3,455.7	3,214.0	2,535.7	12,445.8	11,265
(h) Other expenses	16,879.1	16,234.4	14,575.4	62,816.5	54,775
Total expenses	58,719.5	58,190.8	50,977.5	225,218.0	202,438
4 Profit before share of profit of joint ventures, exceptional items and tax (1+2-3)	7,359.2	6,807.0	7,605.0	26,241.7	35,319
5 Share of loss of joint ventures, net of tax	(58.6)		(41.1)	(116.7)	(312
6 Profit before exceptional items and tax (4+5)	7,300.6	6,801.1	7,563.9	26,125.0	35,007
7 Exceptional items (refer note 4)	8	141	1,627.6	8	1,279
8 Profit before tax (6-7)	7,300.6	6,801.1	5,936.3	26,125.0	33,727
9 Tax expense (refer note 8)					
Current tax	5,803.9	1,360.7	105.2	10,714.8	6,628
Deferred tax	(3,562.4)	530.3	69.7	(3,866.3)	628
Total tax expense	2,241.5	1,891.0	174.9	6,848.5	7,256
0 Profit for the period/year (8-9)	5,059.1	4,910.1	5,761.4	19,276.5	26,471
1 Other comprehensive Income					
A) Items that will not be reclassified subsequently to profit or loss:					
i) Re-measurement of defined employee benefit liability	7.5	22.4	49.2	79.4	12
ii) Equity investments through other comprehensive income – net change in fair	22.3	54.6	(128.5)	(65.8)	81
iii) Income-tax relating to items that will not be reclassified to profit or loss	(0.9)	(5.0)	4.9	(19.5)	(34
B) Items that will be reclassified subsequently to profit or loss:					
i) Exchange differences on translating the financial statements of foreign	101.9	4,693.8	2,180.7	7,361.7	2,557
operations					
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-		12	-	-
Total other comprehensive income/(loss) for the period/year (net of tax)	130.8	4,765.8	2,106.3	7,355.8	2,616
2 Total comprehensive income for the period/year (net of tax) (10+11)	5,189.9	9,675.9	7,867.7	26,632.3	29,087
Attributable to:					
Owners of the Holding Company	5,193.5	9,678.4	7,870.9	26,630.8	29,098
Non-controlling interest	(3.6)	(2.5)	(3.2)	1.5	(10
Out of total comprehensive income above,					
Profit for the year attributable to:					
Owners of the Holding Company	5,062.7	4,912.6	5,764.6	19,275.0	26,481
Non-controlling interest	(3.6)	(2,5)	(3.2)	1.5	(10
Other comprehensive income/(loss) attributable to:					
Owners of the Holding Company	130.8	4,765.8	2,106.3	7,355.8	2,616
Non-controlling interest	2	140	2	1. 2 1	
3 Paid-up equity share capital (face value ₹ 1 per share)	585.9	585.9	585.9	585.9	58
4 Other equity	505.5	0.00.0	505.5	267,812.6	245,173
5 Earnings per equity share (face value ₹ 1 per share)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualised
(a) Basic (in ₹)	8.64	2 C	9	32.90	
(b) Diluted (in ₹)	8.64		1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -	32.90	





к.<u>- 4</u>

Consolidated balance sheet

(All amounts are in ₹ millions, unless otherwise stated)

	(All amounts are in	₹ millions, unless	otherwise stated
SI.		As at	As at
No.	Particulars	31.03.2023	31.03.2022
		Audited	Audited
_			(refer note 10)
	ASSETS		
	Assess Non-current assets		
	Property, plant and equipment	75,433.7	72,204.3
- 1		44,964.0	29,375.6
	Capital work-in-progress	to the second second	5,080.1
	Right-of-use assets	4,520.1	
	Goodwill	5,960.7	4,754.2
	Other intangible assets	24,322.4	23,282.3
	Intangible assets under development	8,936.1	8,096.4
	Investments accounted for using the equity method	900.0	793.5
	Financial assets		
	Investments	3,017.4	5,389.5
	Loans	55.7	63.2
	Trade receivables		05
	Other financial assets	1,503.7	1,289.2
	Deferred tax assets (net)	6,774.9	2,885.9
	Non- current tax assets (net)	2,885.2	3,189.7
	Other non-current assets	4,169.3	1,586.4
	Total non-current assets	183,443.2	157,990.3
2	Current assets		
	Inventories	85,112.3	75,538.5
	Financial assets		
	Investments	1,510.0	3,788.5
	Trade receivables	44,663.8	40,122.6
	Cash and cash equivalents	43,962.9	41,625.1
	Bank balances other than cash and cash equivalents	16,879.1	275.0
	Loans	124.3	127.1
	Other financial assets	2,903.5	709.1
	Current tax assets (net)	756.2	2,699.9
	Other current assets	18,687.0	15,550.1
	Assets held for sale	857.6	791.0
	Total current assets	215,456.7	181,226.9
		213,430.7	101,220.9
	TOTAL ASSETS (1+2)	398,899.9	339,217.2
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	585.9	585.9
	Other equity	267,812.6	245,173.9
	Equity attributable to owners of the Parent Company	268,398.5	245,759.8
	Non-controlling interest	120.0	(19.3
	Total equity	268,518.5	245,740.5
	Liabilities		
	Non-current liabilities		
	Financial liabilities		
	Borrowings	6,189.6	2,492.1
	Lease liabilities	3,215.3	3,186.1
	Others	125.0	113.5
	Provisions	1,727.2	1,717.9
	Deferred tax liabilities (net)	3,896.1	4,109.6
	Other non-current liabilities	290.4	4,103.0
	Total non-current liabilities		11,916.9
		15,443.6	11,910,9
3	Current liabilities		
	Financial liabilities		
	Borrowings	43.435.6	21 225 6
	Lease liabilities	42,425.6	21,235.6
	Trade payables	1,031.6	1,598.9
	total outstanding dues of micro enterprises and small enterprises and total outstanding dues of creditors other than micro enterprises and credit enterprises.	622.7	384.7
	total outstanding dues of creditors other than micro enterprises and small enterprises	38,090.4	26,645.8
	Other financial liabilities	17,213.7	17,746.5
	Other current liabilities	11,432.5	11,662.4
	Provisions	2,005.3	1,705.6
	Current tax liabilities (net)	2,116.0	580.3
	Total current liabilities	114,937.8	81,559.8
	TOTAL EQUITY AND LIABILITIES (1+2+3)	398,899.9	339,217.2



x. _ 4



SI.		For the year	For the year
No.		ended	ended
	Particulars	31.03.2023	31.03.2022
		Audited	Audited (refer note 10)
			1010 107
11	CASH FLOW FROM OPERATING ACTIVITIES Net profit before tax	26,125.0	33,727.4
	Adjustments to reconcile profit before tax to net cash flows:	20,125.0	55,727.4
	Depreciation and amortisation expense	12,445.8	11,265.2
	Allowance for credit losses on trade receivables and other advances (net) Liabilities no longer required written back (net)	524.5 (130.1)	(61.1) (137.8)
	Product destruction expenses / stock written off	(150.1) 56.8	382.8
	Mark-to-market loss/(gain) on derivative financial instruments	(191.4)	(320.2)
	Unrealised foreign exchange gain (net)	(381.4)	(251.8)
	(Profit)/loss on sale / write-off of property, plant and equipment and intangibles under development (net) Reversal of impairment loss on intangible assets/intangible assets under development and goodwill	(132.3) 239.6	1,350.2 (396.3)
	Share of loss of joint ventures	116.7	312.5
	Gain on sale and lease back transactions	8	208.2
	Loss on liquidation of joint ventures/subsidiary Profit on sale of current investment	÷.	26.5 (290.8
	Finance costs	1,289.5	368.4
	Interest income	(1,459.0)	(316.0
1	Effect of exchange rate changes	3,486.0	1,301.4
	Operating profit before working capital changes	41,989.7	47,168.6
	Movements in working capital: (Increase)/decrease in inventories	(9,267.0)	14,975.2
	Increase in trade receivables	(4,321.1)	(4,108.4)
	(Increase)/decrease in other financial assets	(2,204.0)	140.8
	Increase in other current/non-current assets Decrease in Ioans	(3,549.6) 10.4	(34.9) 25.5
	Increase in trade payables	7,076.5	1,106.6
	Increase in provision for retirement benefits and others	217.5	145.2
	(Decrease)/increase in other current/non-current liabilities Increase /(decrease) in other financial liabilities	(1,240.5) 2,328.0	5,573.1 (2,245.0)
	Cash generated from operating activities	31,039.9	62,746.7
	Direct taxes paid (net of refunds)	(7,172.4)	(12,581.9)
	Net cash generated from operating activities (A)	23,867.5	50,164,8
2	CASH FLOW FROM INVESTING ACTIVITIES		
	Purchase of property, plant and equipment, including movement in capital work- in- progress, capital advances and capital creditors (net)	(24,038.0)	(20,529.1)
	Purchase of intangible assets and intangible assets under development	(3,166.0)	(6,517.3)
	Proceeds from sale of property, plant and equipment and intangible assets	110.9	3,809.4
	Acquisition of business (net of settlement of purchase consideration)	(1,689.2)	(5,813.9)
	Purchase of controlling interest in a subsidiary, net of cash and cash equivalents acquired Proceeds from liquidation of subsidiary	(280.5)	- 43.2
	Proceeds from liquidation of joint venture		249.7
	Purchase of non-current investments	(6,769.4)	(2,999.2)
	Proceeds/(purchase) of non-current investments made in joint ventures Proceeds from sale of non-current investments	1,053.8 7,173.2	(726.5 1,352.2
	Purchase of current investments	(13,371.6)	(5,250.3)
	Proceeds from sale of current investments	16,341.5	3,264.3
	Bank balances not considered as cash and cash equivalents (net) Interest received	(16,608.4)	749.3
		1,466.2	252.6
1	Net cash used in investing activities (B)	(39,777.5)	(32,115.6)
3	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds from non-current borrowings	3,822.8	827.3
	Proceeds/(repayment) of current borrowings (net) Finance costs paid	20,753.3 (1,112.0)	(26,366.6) (185.0)
	Repayment of lease liabilities (net)	(924.7)	(1,331.4)
	Dividends paid on equity shares	(4,395.3)	(2,637.0)
	Net cash generated/(used) in from financing activities (C)	18,144.1	(29,692.7)
	Net decrease in cash and cash equivalents (A + B + C)	2,234.1	(11,643.5)
	Cash and cash equivalents at the beginning of the year	41,625.1	53,299.1
	Add: Cash and cash equivalents on acquisition of a subsidiary	64.1	(32.5)
	Effect of exchange differences on cash and cash equivalents	(0.6)	2.0
	Cash and cash equivalents at the end of the year	43,922.7	41,625.1
	Cash and cash equivalents comprise of:		
	Cash on hand	79.5	77.9
	Restricted cash		75.6
	Balance with banks - on current account	16,311.9	22 224 ¢
	- on cash credit account (net)	234.7	23,234.6 336.6
	- in money market	1,365.3	11,603.2
	- on deposit account Cash and cash equivalents considered for cash flows	25,931.3	6,297.2
-	Cash and cash equivalents considered for cash flows	43,922.7	41,625.1
	10 S) k 4		
	* Page 3 of 4		
	artitud Al		

NOTES:

- 1 The above consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results of the Group as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on May 27, 2023. The results for the year ended March 31, 2023 has been audited and for the quarter ended March 31, 2023 has been reviewed by our statutory auditors. The statutory auditors of the Company have expressed an unmodified opinion on the financial results for the year ended March 31, 2023 and have issued an unmodified conclusion in respect of the limited review for the quarter ended March 31, 2023."
- 4 Exceptional items represent the following items which have been credited/(debited) to consolidated statement of profit and loss.

Particulars	For the quarter ended March 31, 2022	For the year ended March 31, 2022
Gain on sale of tangible assets *	3.6	1,160.3
Impairment of intangible assets and goodwill **	(681.2)	(1,490.0)
Impairment of capital work in progress**	(950.0)	(950.0)
Total	(1.627.6)	(1,279,7)

* Gain on sale and lease back of Group's immovable property situated in Dayton, New Jersey, USA.

** Due to uncertain regulatory development and change in business plan impacting the goodwill, intangible assets, capital work in progress relating to certain products, the Group recorded an impairment charge of ₹ 2,440.

5 The Group operates in only one reportable segment viz., 'Pharmaceutical Products'.

6 During the year,

a) Auro Cure Private Limited, India renamed itself as Eugia Steriles Private Limited, w.e.f. July 26, 2022.

b) Wytells Pharma Private Limited, India renamed itself as Eugia SEZ Private Limited, w.e.f. September 2, 2022.

c) Auro Medics Pharma LLC, USA renamed itself as Eugia US LLC, w.e.f. August 8, 2022.

d) TheraNyM Biologics Private Limited, India was incorporated w.e.f. September 22, 2022.

e) PT Aurogen Pharma Indonesia was incorporated w.e.f. July 1, 2022.

f) Auro Steriles LLC was dissolved w.e.f September 30, 2022.

g) Tergene Biotech Pvt.Ltd, India had become Tergene Biotech Limited w.e.f. October 20, 2022.

h) Auro Pharma India Private Limited, India renamed itself as Apitoria Pharma Private limited w.e.f. March 29, 2023.

7 a) The Board of Directors of the Aurobindo Pharma limited (Holding Company) at its meeting held on March 28, 2022 had approved the acquisition of business including certain assets of Veritaz Healthcare Limited (Veritaz). Consequently the Holding Company entered into a definitive agreement with Veritaz for the said acquisition for total consideration of ₹ 1,710 and obtained control effective April 1, 2022 over such business and assets.

b) The Board of Directors of the Holding Company at its meeting held on June 17, 2022 had approved investment in GLS Pharma Limited (GLS) through subscription of 204,819 equity shares for an aggregate consideration of ₹ 93.5 (constituting 17% of the equity share capital of GLS) and acquisition of 409,339 equity shares from the selling shareholders for an aggregate consideration of ₹ 187 (constituting of 34% of equity share capital of GLS). During the quarter ended June 30, 2022, the Holding Company subscribed to 204,819 equity shares of GLS consequent to execution of share subscription and purchase agreement. During the previous quarter on satisfaction of the closing conditions, the Company acquired the additional 409,339 equity shares.

Consequent to the above acquisitions, the results of the current quarter/period are strictly not comparable to the previous quarters/periods.

- 8 During the quarter ended March 31, 2022, the Holding Company elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Holding Company has recognised provision for income tax for the year ended March 31, 2022 and re-measured its deferred tax assets /liabilities based on the rate prescribed in the said Section. The impact of this change has been recognised in the statement of profit and loss during the year ended March 31, 2022.
- 9 The figures for the current quarter and quarter ended March 31, 2022, are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2023 and March 31, 2022, respectively and published year to date figures up to third quarter ended December 31, 2022 and December 31, 2021, respectively, which were subject to limited review by the statutory auditors.
- 10 The consolidated financial results of the Group for the quarter and year ended March 31, 2022, were audited by the M/s BSR & Associates LLP, Chartered Accountants, the predecessor auditor, who have expressed an unmodified opinion.



Place: Hyderabad Date : May 27, 2023 By Order of the Board



K.Nithyananda Reddy Vice Chairman & Managing Director DIN-01284195

Chartered Accountants KRB Towers Plot No.1 to 4 & 4A 1st, 2nd & 3rd Floor Jubilee Enclave, Madhapur Hyderabad-500 081 Telangana, India

Tel: +91 40 7125 3600 Fax: +91 40 7125 3601

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF AUROBINDO PHARMA LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2023 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2023 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of audited consolidated financial results for year ended March 31, 2023 and unaudited consolidated financial results for the quarter ended March 31, 2023" of **AUROBINDO PHARMA LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net loss after tax and total comprehensive loss of its joint ventures and associates for the quarter and year ended March 31, 2023, ("the Statement") being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Audited Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of its subsidiaries, associates and joint ventures referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2023:

- i. includes the results of the subsidiaries, associates and joint ventures listed in Annexure I
- ii. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated total comprehensive income and other financial information of the Group for the year ended March 31, 2023.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2023

With respect to the Consolidated Financial Results for the quarter ended March 31, 2023, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review reports of the other auditors referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2023, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2023

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group, its associates and joint ventures in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2023 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2023, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2023 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group including its associates and joint ventures in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

The respective Board of Directors of the companies included in the Group, its associates and joint ventures are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group, its associates and joint ventures and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group, its associates and joint ventures are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group, its associates and of its jointly controlled entities are responsible for overseeing the financial reporting process of the Group, its associates and joint ventures.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2023

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2023 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered \mathcal{M}

material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of
 accounting and, based on the audit evidence obtained, whether a material uncertainty exists related
 to events or conditions that may cast significant doubt on the ability of the Group, its associates and
 joint ventures to continue as a going concern. If we conclude that a material uncertainty exists, we
 are required to draw attention in our auditor's report to the related disclosures in the Consolidated
 Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are
 based on the audit evidence obtained up to the date of our auditor's report. However, future events
 or conditions may cause the Group and its associates and joint ventures to cease to continue as a
 going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of
 the entities within the Group, its associates and joint ventures to express an opinion on the Annual
 Consolidated Financial Results. We are responsible for the direction, supervision and performance of
 the audit of financial information of such entities included in the Annual Consolidated Financial Results
 of which we are the independent auditors. For the other entities included in the Annual Consolidated
 Financial Results, which have been audited by the other auditors, such other auditors remain
 responsible for the direction, supervision and performance of the audits carried out by them. We
 remain solely responsible for our audit opinion

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

N

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2023

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2023 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SA specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- We did not audit the financial statements of 73 subsidiaries included in the consolidated financial results, whose financial statements/financial information reflect total assets of ₹ 277,241.7 million as at March 31, 2023 and total revenues of ₹ 41,577.6 million and ₹ 163,982.4 million for the quarter and year ended March 31, 2023 respectively, total net (loss) / profit after tax of ₹ (510.9) million and ₹ 5,348.7 million for the quarter and year ended March 31, 2023 respectively and total comprehensive (loss) / income of ₹ (512.6) million and ₹ 5,352.1 million for the quarter and year ended March 31, 2023 respectively and net cash flows (net) of ₹ 3,371.7 million for the year ended March 31, 2023, as considered in the Statement. The consolidated financial results also includes the Group's share of loss after tax of ₹ (45.1) million and ₹ (120.8) million for the quarter and year ended March 31, 2023 respectively and Total comprehensive loss of ₹ (45.0) million and ₹ (120.7) million for the quarter and year ended March 31, 2023 respectively, as considered in the Statement, in respect of 6 joint ventures whose financial statements have not been audited by us. These financial statements have been audited, as applicable, by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above. N

The consolidated financial results also includes the Group's share of loss after tax of ₹ (12.0) million and ₹ (12.0) million for the quarter and year ended March 31, 2023 respectively and total comprehensive loss of ₹ (12.0) million and ₹ (12.0) million for the quarter and year ended March 31, 2023 respectively, as considered in the Statement, in respect of 2 associates whose financial information have not been audited by us. These financial information are unaudited and have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these associates, is based solely on such unaudited financial information. In our opinion and according to the information and explanations given to us by the Board of Directors, these financial information are not material to the Group.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

For **DELOITTE HASKINS & SELLS** Chartered Accountants (Firm's Registration No. 008072S)

wind

C Manish Muralidhar (Partner) (Membership No. 213649)

Place: Hyderabad Date: May 27, 2023 UDIN: 23213649BGVBYR2464

Annexure I to the Independent Auditor's Report on Audit of Annual Consolidated Financial results and review of Quarterly financial Results

The annual consolidated financial results includes results of the following entities:

S.No	Name of the entity	Country	Relationship
1	Helix Healthcare B.V.	The Netherlands	Direct Subsidiary
2	APL Pharma Thai Limited	Thailand	Direct Subsidiary
3	Aurobindo Pharma Industria Farmaceutica Ltd	Brazil	Direct Subsidiary
4	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Direct Subsidiary
5	All Pharma (Shanghai) Trading Co Ltd	China	Direct Subsidiary
6	Aurobindo Pharma USA Inc.	USA	Direct Subsidiary
7	APL Healthcare Limited	India	Direct Subsidiary
8	Auronext Pharma Private Limited	India	Direct Subsidiary
9	Auro Peptides Ltd	India	Direct Subsidiary
10	Auro Pharma India Private Limited	India	Direct Subsidiary
11	Auroactive Pharma Private Limited	India	Direct Subsidiary
12	CuraTeQ Biologics Private Limited	India	Direct Subsidiary
13	AuroZest Private Limited	India	Direct Subsidiary
14	Aurobindo Antibiotics Private Limited	India	Direct Subsidiary
15	Eugia Pharma Specialities Ltd	India	Direct Subsidiary
16	Mviyes Pharma Ventures Private Limited	India	Direct Subsidiary
17	Auro vaccines Private Limited	India	
18		India	Direct Subsidiary
	GLS Pharma Limited (w.e.f. August 17, 2022) Agile Pharma B.V.		Direct Subsidiary
19	,	The Netherlands	Step-Down Subsidia
20	Laboratorios Aurobindo S.L.	Spain	Step-Down Subsidia
21	Aurex B.V. (formerly known as Pharmacin B.V.)	The Netherlands	Step-Down Subsidia
22	Milpharm Limited	U.K.	Step-Down Subsidia
23	Aurobindo Pharma (Malta) Ltd	Malta	Step-Down Subsidia
24	APL Swift Services (Malta) Ltd	Malta	Step-Down Subsidia
25	Aurobindo Pharma (Romania) s.r.l	Romania	Step-Down Subsidia
26	Pharmacin B.V. (formerly known as Aurex B.V.)	The Netherlands	Step-Down Subsidia
27	Aurovitas Pharma Polska	Poland	Step-Down Subsidia
28	Generis Farmaceutica S.A.	Portugal	Step-Down Subsidia
29	Generis Phar, Unipessoal Lda	Portugal	Step-Down Subsidia
30	Aurobindo Pharma (Italia) S.r.l	Italy	Step-Down Subsidia
31	Arrow Generiques SAS	France	Step-Down Subsidia
32	1980 Puren Pharma GmbH (formerly Actavis Management GmbH), Germany	Germany	Step-Down Subsidia
33	Puren Pharma GmbH & Co., KG (formerly Actavis Deutschland GmbH & Co., KG)	Germany	Step-Down Subsidia
34	Aurovitas Spain SA (formerly Actavis Spain S.A)	Spain	Step-Down Subsidia
35	Aurobindo Pharma B.V. (formerly known as Actavis B.V.)	The Netherlands	Step-Down Subsidia
36	Aurovitas Spol s.r.o (Formerly Apotex (CR) Spol s.r.o.)	Czech Rebublic	Step-Down Subsidia
37	Apotex Europe B.V.	The Netherlands	Step-Down Subsidia
38	Aurovitas Nederland B.V (formerly Apotex Nederland B.V.)	The Netherlands	Step-Down Subsidia
39	Sameko Farma B.V.	The Netherlands	Step-Down Subsidia
40	Leidapharm B.V.	The Netherlands	Step-Down Subsidia
41	Marel B.V.	The Netherlands	Step-Down Subsidia
42	Pharma Dossier B.V.	The Netherlands	Step-Down Subsidia
43	Aurobindo NV/SA	Belgium	Step-Down Subsidia
44	CuraTeQ Biologics s.r.o.	Czech Rebublic	Step-Down Subsidia
45	Eugia Pharma B.V.	The Netherlands	Step-Down Subsidia
46	Eugla Pharma (Malta) Limited (w.e.f. October 14, 2021)	Malta	Step-Down Subsidia
47	Eugia (UK) Limited	U.K.	Step-Down Subsidia
7/		U.N.	Steb-Down Supsidia

S.No	Name of the entity	Country	Relationship
48	Auro Pharma Inc.	Canada	Step-Down Subsidiary
49	Aurobindo Pharma (Pty) Ltd	South Africa	Step-Down Subsidiary
50	Aurobindo Pharma Japan KK	Japan	Step-Down Subsidiary
51	Aurovida Farmaceutica SA DE CV	Mexico	Step-Down Subsidiary
52	Aurobindo Pharma Colombia S A S	Colombia	Step-Down Subsidiary
53	Aurogen South Africa (PTY) Ltd	South Africa	Step-Down Subsidiary
54	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Step-Down Subsidiary
55	Aurovitas Pharma (Taizhou) Ltd	China	Step-Down Subsidiary
56	Aurobindo Pharma FZ-LLC	Dubai	Step-Down Subsidiary
57	Aurosalud SA De CV	Mexico	Step-Down Subsidiary
58	Auro PR Inc	Puerto Rico	Step-Down Subsidiary
59	Eugia Pharma Inc. (w.e.f. October 29, 2021)	Canada	Step-Down Subsidiary
60	Eugia Pharma (Australia) PTY Limited	Australia	Step-Down Subsidiary
61	Eugia Pharma Industria Farmaceutica Limitada (w.e.f. December 20 2021)	Brazil	Step-Down Subsidiary
62	Auro PR I LLC (merged with Auro PR Inc. on May 23, 2022)	Puerto Rico	Step-Down Subsidiary
63	Aurobindo Pharma Ukraine LLC	Ukraine	Step-Down Subsidiary
64	Eugia Pharma Colombia S.A.S. (w.e.f. March 02, 2022)	Colombia	Step-Down Subsidiary
65	PT Aurogen Pharma Indonesia (w.e.f. July 01 2022)	Indonesia	Step-Down Subsidiary
66	Auroscience PTY Ltd, Australia	Australia	Step-Down Subsidiary
67	Aurolife Pharma LLC	USA	Step-Down Subsidiary
68	Auro Health LLC	USA	Step-Down Subsidiary
69	Auro AR LLC, USA	USA	Step-Down Subsidiary
70	Auro Vaccines LLC	USA	Step-Down Subsidiary
71	AuroLogistics LLC	USA	Step-Down Subsidiary
72	Acrotech Biopharma Inc. (formerly Acrotech Biopharma LLC)	USA	Step-Down Subsidiary
73	Auro Science LLC	USA	Step-Down Subsidiary
74	Auro Packaging LLC	USA	Step-Down Subsidiary
75	Vespyr Brands, Inc (formerly known as Nurya Brands Inc)	USA	Step-Down Subsidiary
76	Eugia Injectable Inc (closed w.e.f. April 26, 2022)	USA	Step-Down Subsidiary
77	Eugia Inc. (w.e.f February 23, 2022)	USA	Step-Down Subsidiary
78	Eugia US LLC (formerly known as Auro Medics Pharma LLC)	USA	Step-Down Subsidiary
79	Auro Steriles LLC (dissolved w.e.f September 30, 2022 and certified on November 16, 2022)	USA	Step-Down Subsidiary
80	Eugia US Manufacturing LLC (w.e.f. August 31, 2021)	USA	Step-Down Subsidiary
81	Eugia Steriles Private Limited (formerly known as Auro Cure Private Limited)	India	Step-Down Subsidiary
82	Lyfius Pharma Private Limited	India	Step-Down Subsidiary
83	Qule Pharma Private Limited	India	Step-Down Subsidiary
84	Eugla SEZ Private Limited (formerly Wytells Pharma Private Limited)	India	Step-Down Subsidiary
85	Theranym Biologics Private Limited (w.e.f September 22 2022)	India	Step-Down Subsidiary
86	Novagen Pharma (Pty) Ltd	South Africa	Joint venture
87	Purple Bellflower, South Africa	South Africa	Joint venture
88	Luoxin Aurovitas Pharm (Chengdu) Co. Ltd.	China	Joint venture
89	Novagen BBBEE Invest Co (Pty) Ltd	South Africa	Joint venture
90	Raidurgam Developers Limited (Formerly Aurobindo Antibiotics Ltd)	India	Joint venture
91	Tergene Biotech Limited (formerly known as Tergene Biotech Pvt.Ltd)	India	Joint venture
92	NVNR (Ramannapet I) Power Plant Private Limited	India	Associate
93	NVNR (Ramannapet II) Power Plant Private Limited	India	Associate

y